Liver Cancer

There are multiple clinical trials underway for individuals with liver cancer. For a more comprehensive list of Nexavar® (sorafenib) clinical trials, please visit clinicaltrials.gov or call 866-639-2827.

Phase 3 Study of Nexavar in Adjuvant Setting - STORM
Enrollment complete
Study Design: Randomized, double-blind, placebo-controlled study
Patients: Patients with HCC treatment following surgery or local treatment
Purpose: To compare the efficacy of Nexavar as an adjuvant treatment by assessing recurrence free survival, as well as differences in time to recurrence and overall survival
Location: North America, South America, Europe, and the Asia-Pacific region

Phase 3 Study of Nexavar in Combination with Tarceva® (erlotinib) - SEARCH
Enrollment Complete
Study Design: Randomized, double-blind, placebo-controlled trial
Patients: Patients with unresectable, advanced or metastatic Child-Pugh A measurable liver cancer and who have had prior local therapy
Purpose: To determine the effectiveness of Nexavar plus Erlotinib when compared to Nexavar alone by assessing the difference in overall survival (OS), as well as to evaluate other measures of efficacy and safety
Location: Multiple centers throughout North America, Europe and the Asia-Pacific region

Phase 2 Study of Nexavar in Combination with TACE - SPACE
Enrollment Complete
Study Design: Randomized, double-blind, placebo-controlled study
Patients: Patients amenable to TACE
Purpose: To determine the effectiveness of Nexavar in combination with TACE compared to Nexavar alone by assessing the difference in time to progression (TTP) and overall survival (OS), as well as to evaluate other measures of efficacy and safety
Location: Multiple centers throughout North America, Europe and the Asia-Pacific region

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204